Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation.

Wagenaar TR, Zabludoff S, Ahn SM, Allerson C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, Huang SM, Jiang L, Kim D, Metz-Weidmann C, Pavlicek A, Pollard J, Reeves J, Rocnik JL, Scheidler S, Shi C, Sun F, Tolstykh T, Weber W, Winter C, Yu E, Yu Q, Zheng G, Wiederschain D.

Mol Cancer Res. 2015 Mar 10. [Epub ahead of print]

PMID:
25758165
2.

MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis.

D'Angelo E, Vicentini C, Agostini M, Kiss A, Baffa R, Scarpa A, Fassan M.

Curr Drug Targets. 2015;16(4):383-92.

PMID:
25495924
3.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R.

J Natl Cancer Inst. 2014 Oct 11;106(12). pii: dju324. doi: 10.1093/jnci/dju324. Print 2014 Dec. Erratum in: J Natl Cancer Inst. 2014 Nov:106(11):dju373doi:10.1093/jnci/dju373. Garzon, Maria Elena Sana Ramiro [Corrected to Garzon, Ramiro and Sana, Maria Elena].

PMID:
25306216
4.

Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis.

Fassan M, Dall'Olmo L, Galasso M, Braconi C, Pizzi M, Realdon S, Volinia S, Valeri N, Gasparini P, Baffa R, Souza RF, Vicentini C, D'Angelo E, Bornschein J, Nuovo GJ, Zaninotto G, Croce CM, Rugge M.

Oncotarget. 2014 Aug 30;5(16):7162-71.

5.

Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) and mitostatin.

Neill T, Torres A, Buraschi S, Owens RT, Hoek JB, Baffa R, Iozzo RV.

J Biol Chem. 2014 Feb 21;289(8):4952-68. doi: 10.1074/jbc.M113.512566. Epub 2014 Jan 8.

6.

Advanced precancerous lesions within the GI tract: the molecular background.

Fassan M, Baffa R, Kiss A.

Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):159-69. doi: 10.1016/j.bpg.2013.03.009. Review.

PMID:
23809238
7.

MicroRNAs and targeted therapy: small molecules of unlimited potentials.

Fassan M, Baffa R.

Curr Opin Genet Dev. 2013 Feb;23(1):75-7. doi: 10.1016/j.gde.2013.02.009. Epub 2013 Mar 22. No abstract available.

PMID:
23523049
8.

MicroRNA dysregulation in esophageal neoplasia: the biological rationale for novel therapeutic options.

Fassan M, Baffa R, Kiss A, Zaninotto G, Rugge M.

Curr Pharm Des. 2013;19(7):1236-41. Review.

PMID:
23092347
9.

Role of miRNA in distinguishing primary brain tumors from secondary tumors metastatic to the brain.

Fassan M, Sachsenmeir K, Rugge M, Baffa R.

Front Biosci (Schol Ed). 2011 Jun 1;3:970-9. Review.

PMID:
21622246
10.

Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells.

Fassan M, D'Arca D, Letko J, Vecchione A, Gardiman MP, McCue P, Wildemore B, Rugge M, Shupp-Byrne D, Gomella LG, Morrione A, Iozzo RV, Baffa R.

PLoS One. 2011 May 6;6(5):e19771. doi: 10.1371/journal.pone.0019771.

11.

MicroRNA expression profiling in human Barrett's carcinogenesis.

Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, Battaglia G, Parente P, Croce CM, Zaninotto G, Ancona E, Rugge M.

Int J Cancer. 2011 Oct 1;129(7):1661-70. doi: 10.1002/ijc.25823. Epub 2011 Mar 11.

12.

Trichoplein/mitostatin regulates endoplasmic reticulum-mitochondria juxtaposition.

Cerqua C, Anesti V, Pyakurel A, Liu D, Naon D, Wiche G, Baffa R, Dimmer KS, Scorrano L.

EMBO Rep. 2010 Nov;11(11):854-60. doi: 10.1038/embor.2010.151. Epub 2010 Oct 8.

13.

Reprogramming of miRNA networks in cancer and leukemia.

Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM.

Genome Res. 2010 May;20(5):589-99. doi: 10.1101/gr.098046.109.

14.

The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin.

Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, Alberghina L, Vanoni M, Baffa R, Gomella LG, Iozzo RV, Morrione A.

Am J Pathol. 2010 Jun;176(6):2997-3006. doi: 10.2353/ajpath.2010.090904. Epub 2010 Apr 15.

15.

Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.

Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.

Oncogene. 2009 Dec 10;28(49):4344-52. doi: 10.1038/onc.2009.286. Epub .

PMID:
19784068
16.

Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE.

Clin Cancer Res. 2009 Sep 1;15(17):5338-49. doi: 10.1158/1078-0432.CCR-08-2865. Epub 2009 Aug 25.

17.

MicroRNA expression profiling of male breast cancer.

Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM, Rosenberg A.

Breast Cancer Res. 2009;11(4):R58. doi: 10.1186/bcr2348. Epub 2009 Aug 10.

18.

MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets.

Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, Gardiman M, Rugge M, Gomella LG, Croce CM, Rosenberg A.

J Pathol. 2009 Oct;219(2):214-21. doi: 10.1002/path.2586.

PMID:
19593777
19.

BaS analysis: suggesting a new cephalometric model in follow-up of patients with craniostenosis who underwent craniofacial advancement surgery after 1 year from the end of the distraction protocol.

Gasparini G, Cacucci L, Di Nardo F, Moro A, Boniello R, Baffa R, Deli R, Pelo S.

J Craniofac Surg. 2009 May;20(3):895-8. doi: 10.1097/SCS.0b013e3181a2ef62.

PMID:
19381100
20.

Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor.

D'Arca D, LeNoir J, Wildemore B, Gottardo F, Bragantini E, Shupp-Byrne D, Zanesi N, Fassan M, Croce CM, Gomella LG, Baffa R.

Urol Oncol. 2010 Mar-Apr;28(2):189-94. doi: 10.1016/j.urolonc.2009.01.016. Epub 2009 Apr 16.

PMID:
19372053
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk